Cordycepin — Safety, Research, Risks & Legal Status

Not medical advice. Cordycepin is discussed here for informational and harm-reduction purposes only. We do not endorse use, and any dosing context is informational, not a protocol.

Also known as	3'-Deoxyadenosine; 3-Deoxyadenosine; NUC-7738 (ProTide derivative)
Category	Research Chemical
Chemical class	Purine nucleoside analogue (adenosine derivative, 3'-deoxy)
Natural source	Cordyceps sinensis (Ophiocordyceps sinensis) fungus
Oral bioavailability	Estimated below 20% due to rapid adenosine deaminase (ADA) metabolism
Lead pharmaceutical candidate	NUC-7738 (ProTide formulation, NuCana plc) - Phase I completed circa 2021, ~40x preclinical potency vs. parent
Primary development obstacle	Systemic deamination by ADA limits systemic exposure of unmodified cordycepin
Human evidence level	Cordyceps extracts: small completed trials (COPD, immunity, insomnia); isolated cordycepin: Phase I safety data only, no efficacy RCTs
US legal status	Cordycepin as an isolated compound has no FDA-approved indication and no approved regulatory pathway in the US. It is available as an unlicensed supplement ingredient or research chemical. Cordyceps fungal products broadly have GRAS (Generally Recognized as Safe) designation from the FDA, but this does not extend to isolated pharmaceutical-grade cordycepin. The ProTide derivative NUC-7738, under development by NuCana plc (UK), has completed a Phase I trial but remains investigational with no approved status in any jurisdiction as of the knowledge cutoff.

What is Cordycepin?

Cordycepin is a purine nucleoside analogue - specifically, an adenosine derivative in which the hydroxyl group at the 3' position of the ribose ring is absent - naturally occurring in Cordyceps sinensis, a parasitic fungus used for centuries in traditional Tibetan and Chinese medicine. As an isolated compound, it has attracted substantial preclinical research interest for anti-cancer, anti-inflammatory, and immunomodulatory properties. Its translation to clinical medicine is significantly hindered by rapid in vivo deamination by adenosine deaminase (ADA), which severely limits oral bioavailability (estimated below 20%) and systemic exposure. A ProTide prodrug formulation (NUC-7738) designed to bypass this barrier has completed early-phase human trials.

How it works

Cordycepin exerts multiple mechanistic effects at the cellular level. It inhibits mRNA polyadenylation and protein synthesis, disrupting gene expression in proliferating cells. Inside cancer cells it is phosphorylated to its active metabolite 3'-dATP, which acts as a cytotoxic chain terminator. Anti-inflammatory activity has been attributed to suppression of the NF-kB pathway via inhibition of Akt and p38 kinase signaling, and to inhibition of NLRP3 inflammasome/Caspase-1/GSDMD-mediated pyroptosis in macrophage models. Cordycepin also modulates AMPK, mTOR, PI3K/Akt, and MAPK pathways, which are relevant to both metabolic and oncological contexts. A rodent study identified a rapid antidepressant-like effect attributed to enhancement of prefrontal AMPA receptor signaling. The majority of mechanistic evidence derives from in vitro cell models and animal studies; direct translation of these mechanisms to humans has not been established in controlled trials.

Background & history

Cordyceps sinensis has been used in Himalayan and Chinese traditional medicine for centuries, historically valued as a tonic for fatigue, respiratory conditions, and vitality. Cordycepin was isolated as the bioactive nucleoside constituent and characterized structurally in the mid-20th century. Preclinical interest accelerated in the 2000s and 2010s as molecular targets were identified. Academic groups at Oxford University, Cardiff University, and multiple Chinese research institutes have produced extensive preclinical literature. NuCana plc (UK) developed NUC-7738, a ProTide formulation intended to overcome the ADA deamination barrier, and completed a first-in-human Phase I trial with results reported circa 2021, showing approximately 40-fold greater potency over the parent compound in preclinical comparisons. Phase II planning was reported but clinical development status in 2026 is not confirmed in available sources.

What the research says

Research on cordycepin spans three distinct tiers that should not be conflated. First, preclinical evidence is substantial: robust animal and cell-culture data support anti-cancer activity (including synergy with cisplatin and doxorubicin), anti-inflammatory effects in LPS-stimulated macrophage models, and signals in diabetes and respiratory disease models. Second, Cordyceps extract human trials (not isolated cordycepin) are small-scale but completed: studies with fewer than 200 participants have reported improvements in COPD symptoms, immune markers, and insomnia with a favorable safety profile. Third, isolated pharmaceutical cordycepin human efficacy trials are essentially absent; only Phase I safety and pharmacokinetic data for NUC-7738 have been published. No large randomized controlled trial has evaluated isolated cordycepin for any indication. An animal study identified a rapid antidepressant signal via AMPA receptor pathways, but no human replication exists. Overall: mechanistically interesting, preclinically active, clinically unproven as of available evidence.

Reported effects

Preclinical anti-tumor activity attributed to 3'-dATP cytotoxic metabolite formation and cell cycle disruption (animal and cell models only)
Anti-inflammatory effects via NF-kB, Akt, p38 suppression and NLRP3 inflammasome inhibition demonstrated in preclinical models
Immunomodulatory effects reported in small human Cordyceps extract trials (improved immune markers, CD4/CD8 ratios); not confirmed for isolated cordycepin
COPD symptom improvement and respiratory benefit reported in small Cordyceps extract trials; isolated cordycepin not studied in humans for this indication
Rapid antidepressant-like effect observed in one rodent study via prefrontal AMPA receptor signaling; no human data
Potential AMPK/mTOR metabolic modulation in preclinical models relevant to diabetes and energy metabolism; human evidence absent
General fatigue-reduction and tonic effects attributed to Cordyceps preparations in traditional use; clinical trial evidence is limited and confounded by whole-extract composition

Dosing & administration (informational)

Published literature on Cordyceps extract human trials has used oral doses generally in the range of 1-4 grams per day of whole-fungus preparations, but these figures reflect mixed-component extracts and cannot be directly translated to isolated cordycepin equivalents. No dose-ranging study for isolated oral cordycepin in humans exists, largely because oral bioavailability is severely limited by ADA-mediated deamination. The NUC-7738 Phase I trial administered the compound intravenously under clinical supervision with dose escalation protocols. These figures are presented as literature context only and do not constitute a protocol or recommendation. Appropriate use of any cordycepin-containing product in a clinical context requires evaluation by a licensed clinician.

This is general research/context information, not medical advice or a recommended protocol.

Safety & side effects

Cordyceps extracts in completed human trials described as well tolerated with uncommon and minimal adverse effects; no hepatotoxicity or significant ALT elevations reported (NIH LiverTox assessment)
Isolated cordycepin: human safety data are sparse; no published cases of acute organ injury at supplement doses
Rapid systemic deamination by ADA is the primary pharmacokinetic liability; theoretical risk of tissue accumulation of metabolites has not been confirmed clinically
NUC-7738 Phase I trial reported no dose-limiting toxicities at doses tested, but full safety dataset for higher doses is not publicly available in detail
Drug interaction potential with other nucleoside analogues, ADA inhibitors (e.g., pentostatin), or immunosuppressants is theoretically plausible but unstudied in humans
Confidence in the safety profile is limited by the small number and scale of human studies; absence of evidence of harm is not equivalent to a confirmed favorable safety profile
Individuals with ADA deficiency, purine metabolism disorders, or on concurrent nucleoside analogue therapies face unknown but potentially elevated risk

Drug & supplement interactions

N
o
f
o
r
m
a
l
h
u
m
a
n
d
r
u
g
i
n
t
e
r
a
c
t
i
o
n
s
t
u
d
i
e
s
f
o
r
i
s
o
l
a
t
e
d
c
o
r
d
y
c
e
p
i
n
h
a
v
e
b
e
e
n
p
u
b
l
i
s
h
e
d
.
M
e
c
h
a
n
i
s
t
i
c
c
o
n
s
i
d
e
r
a
t
i
o
n
s
s
u
g
g
e
s
t
p
o
t
e
n
t
i
a
l
i
n
t
e
r
a
c
t
i
o
n
s
w
i
t
h
:
a
d
e
n
o
s
i
n
e
d
e
a
m
i
n
a
s
e
i
n
h
i
b
i
t
o
r
s
s
u
c
h
a
s
p
e
n
t
o
s
t
a
t
i
n
o
r
c
l
a
d
r
i
b
i
n
e
,
w
h
i
c
h
c
o
u
l
d
i
n
c
r
e
a
s
e
c
o
r
d
y
c
e
p
i
n
s
y
s
t
e
m
i
c
e
x
p
o
s
u
r
e
u
n
p
r
e
d
i
c
t
a
b
l
y
;
o
t
h
e
r
n
u
c
l
e
o
s
i
d
e
a
n
a
l
o
g
u
e
s
u
s
e
d
i
n
o
n
c
o
l
o
g
y
o
r
a
n
t
i
v
i
r
a
l
t
h
e
r
a
p
y
,
w
h
e
r
e
o
v
e
r
l
a
p
p
i
n
g
m
e
c
h
a
n
i
s
m
s
c
o
u
l
d
c
o
m
p
o
u
n
d
t
o
x
i
c
i
t
y
;
i
m
m
u
n
o
s
u
p
p
r
e
s
s
a
n
t
s
,
g
i
v
e
n
c
o
r
d
y
c
e
p
i
n
'
s
i
m
m
u
n
o
m
o
d
u
l
a
t
o
r
y
p
r
e
c
l
i
n
i
c
a
l
p
r
o
f
i
l
e
.
C
o
r
d
y
c
e
p
s
e
x
t
r
a
c
t
s
h
a
v
e
n
o
t
b
e
e
n
s
y
s
t
e
m
a
t
i
c
a
l
l
y
s
t
u
d
i
e
d
f
o
r
d
r
u
g
i
n
t
e
r
a
c
t
i
o
n
s
.
T
h
e
c
y
t
o
c
h
r
o
m
e
P
4
5
0
i
n
t
e
r
a
c
t
i
o
n
p
r
o
f
i
l
e
o
f
c
o
r
d
y
c
e
p
i
n
i
s
n
o
t
e
s
t
a
b
l
i
s
h
e
d
i
n
h
u
m
a
n
s
.

Who should avoid it

Use with other nucleoside analogue drugs without medical supervision (overlapping mechanisms, unknown additive toxicity)
Use with adenosine deaminase inhibitors (pentostatin) - unpredictable pharmacokinetic interaction
Reliance on isolated cordycepin supplements as a substitute for evaluated cancer or inflammatory disease treatment
High-dose or intravenous self-administration; parenteral routes have only been studied in controlled Phase I settings
Use during pregnancy or lactation - no human safety data exist for these populations
Sourcing from unverified suppliers without independent assay confirming cordycepin content and absence of contaminants

How it is commonly combined

No controlled human data exist on cordycepin combinations. Preclinical studies have shown synergistic anti-tumor activity when cordycepin was combined with cisplatin and doxorubicin in cell models, but these findings have not been translated to human trials. The general supplement market pairs Cordyceps extracts with other adaptogens such as lion's mane or reishi, but these combinations are without rigorous human evidence. Combining cordycepin with ADA inhibitors would be high-risk without clinical oversight.

Legal & regulatory. Cordycepin as an isolated compound has no FDA-approved indication and no approved regulatory pathway in the US. It is available as an unlicensed supplement ingredient or research chemical. Cordyceps fungal products broadly have GRAS (Generally Recognized as Safe) designation from the FDA, but this does not extend to isolated pharmaceutical-grade cordycepin. The ProTide derivative NUC-7738, under development by NuCana plc (UK), has completed a Phase I trial but remains investigational with no approved status in any jurisdiction as of the knowledge cutoff.

Quality & harm reduction

C
o
r
d
y
c
e
p
s
s
i
n
e
n
s
i
s
i
s
c
u
l
t
i
v
a
t
e
d
a
t
i
n
d
u
s
t
r
i
a
l
s
c
a
l
e
i
n
C
h
i
n
a
,
T
i
b
e
t
,
a
n
d
N
e
p
a
l
;
p
r
o
d
u
c
t
q
u
a
l
i
t
y
i
n
t
h
e
s
u
p
p
l
e
m
e
n
t
m
a
r
k
e
t
i
s
h
i
g
h
l
y
v
a
r
i
a
b
l
e
.
T
h
i
r
d
-
p
a
r
t
y
t
e
s
t
i
n
g
f
o
r
a
c
t
u
a
l
c
o
r
d
y
c
e
p
i
n
c
o
n
t
e
n
t
i
n
c
o
m
m
e
r
c
i
a
l
C
o
r
d
y
c
e
p
s
p
r
o
d
u
c
t
s
i
s
i
n
c
o
n
s
i
s
t
e
n
t
,
a
n
d
l
a
b
e
l
e
d
c
o
n
c
e
n
t
r
a
t
i
o
n
s
a
r
e
f
r
e
q
u
e
n
t
l
y
u
n
v
e
r
i
f
i
e
d
.
W
i
l
d
-
h
a
r
v
e
s
t
e
d
O
p
h
i
o
c
o
r
d
y
c
e
p
s
s
i
n
e
n
s
i
s
(
t
h
e
a
u
t
h
e
n
t
i
c
s
p
e
c
i
e
s
)
c
o
m
m
a
n
d
s
a
p
r
e
m
i
u
m
a
n
d
i
s
d
i
s
t
i
n
c
t
f
r
o
m
c
u
l
t
u
r
e
d
m
y
c
e
l
i
u
m
p
r
o
d
u
c
t
s
,
w
h
i
c
h
m
a
y
d
i
f
f
e
r
s
u
b
s
t
a
n
t
i
a
l
l
y
i
n
c
o
r
d
y
c
e
p
i
n
c
o
n
c
e
n
t
r
a
t
i
o
n
.
P
h
a
r
m
a
c
e
u
t
i
c
a
l
-
g
r
a
d
e
i
s
o
l
a
t
e
d
c
o
r
d
y
c
e
p
i
n
i
s
a
v
a
i
l
a
b
l
e
a
s
a
r
e
s
e
a
r
c
h
c
h
e
m
i
c
a
l
f
r
o
m
c
h
e
m
i
c
a
l
s
u
p
p
l
i
e
r
s
b
u
t
i
s
n
o
t
m
a
n
u
f
a
c
t
u
r
e
d
u
n
d
e
r
G
M
P
f
o
r
h
u
m
a
n
u
s
e
.
C
o
n
s
u
m
e
r
s
s
h
o
u
l
d
t
r
e
a
t
s
u
p
p
l
e
m
e
n
t
c
l
a
i
m
s
a
b
o
u
t
c
o
r
d
y
c
e
p
i
n
c
o
n
t
e
n
t
a
s
u
n
v
e
r
i
f
i
e
d
a
b
s
e
n
t
i
n
d
e
p
e
n
d
e
n
t
a
s
s
a
y
.

Safer, legal alternative we recommend

Sleepio Formula. For the same sleep goal, our Sleep Formula is a legal, non-prescription option you can buy now.

See our recommended pick

Find Cordycepin →

Know your numbers before you research

Order your own bloodwork online — hormone, metabolic and inflammation panels, no doctor visit needed. Know your baselines before and during any protocol. Independent bloodwork is the cheapest insurance there is.

Get tested with Ulta Lab Tests →

Frequently asked questions

Is cordycepin the same as Cordyceps?

No. Cordyceps sinensis is a fungus used in traditional medicine; cordycepin is one isolated bioactive compound found within it. Commercial Cordyceps supplements typically contain a mixture of compounds and variable cordycepin content. The research evidence base for whole Cordyceps extracts and for isolated cordycepin should not be conflated.

What human evidence exists for cordycepin's anti-cancer effects?

Anti-cancer evidence for isolated cordycepin in humans is essentially limited to Phase I safety and pharmacokinetic data for the ProTide derivative NUC-7738. No human efficacy trial for cancer has been published for either isolated cordycepin or NUC-7738. Preclinical cell and animal data are substantial but have not yet been replicated in controlled human studies.

What dose should I take?

Dosing guidance for cordycepin as an isolated compound is not appropriate to provide here. No dose-ranging human efficacy study has established safe or effective doses for any indication. Whole Cordyceps extract doses used in small human trials are not directly translatable to isolated cordycepin. A licensed clinician should be consulted before any use intended to address a health condition.

Why is cordycepin's bioavailability a problem?

The enzyme adenosine deaminase (ADA), present in blood and tissues, rapidly converts cordycepin to a less active form (3'-deoxyinosine) before it can reach target tissues at meaningful concentrations. This is estimated to reduce effective oral exposure to below 20% of the administered dose. NuCana's NUC-7738 uses ProTide chemistry - a prodrug approach that delivers the active metabolite intracellularly while bypassing ADA - to address this barrier.

Is cordycepin legal in the United States?

Cordycepin is not approved by the FDA for any medical indication and has no approved pharmaceutical status. Cordyceps fungal products have GRAS designation, and cordycepin-containing supplements are sold legally in the US. However, isolated cordycepin positioned for therapeutic use would be classified as an unapproved drug. NUC-7738 is investigational and not approved anywhere.

Are there safety concerns with cordycepin supplements?

Cordyceps extract products have shown a favorable tolerability profile in small human trials, with no hepatotoxicity signals and minimal adverse effects. Isolated cordycepin human safety data are sparse. The absence of reported serious adverse events in the limited published literature should not be interpreted as a confirmed safety clearance, as study populations were small and monitoring may not have captured rare events. Individuals on nucleoside analogue drugs or with purine metabolism disorders face unknown risks.

References & further reading

PubMed: cordycepin mechanism anti-inflammatory AMPK NF-kB review 2021-2024
PubMed: 3'-deoxyadenosine cancer nucleoside analogue preclinical mechanism
PubMed: cordycepin rapid antidepressant AMPA receptor (PMID 26443809)
PubMed: NUC-7738 ProTide cordycepin Phase I clinical trial NuCana (PMC9401491)
ClinicalTrials.gov: NCT07258160 cordycepin CD8 lymphocytopenia solid tumors; NCT02814617 Cordyceps sinensis mycelium immunity